abs360.txt	background		prostate	cancer	incidence	rates	vary	25-fold	worldwide		differencesin	psa	screening	are	largely		but	not	entirely		responsible		we	examinedgeographic	differences	in	prevalence	of	histologic	prostate	inflammation	andsubsequent	prostate	cancer	risk	methods		seven	thousand	nonhispanic	white	menwere	enrolled	in	the	reduction	by	dutasteride	of	prostate	cancer	events	(reduce)trial	from	europe	(n	=	4	644)		north	america	(n	=	1	746)		south	america	(n	=466)		and	australia/new	zealand	(n	=	144)		histologic	inflammation	in	baselinenegative	prostate	biopsies	was	classified	as	chronic	(lymphocytes/macrophages)	oracute	(neutrophils)		multivariable	logistic	regression	was	used	to	examineassociations	between	region	and	prostate	inflammation		and	between	region	andprostate	cancer	risk	at	2-year	biopsy	results		prevalence	of	prostateinflammation	varied	across	region		with	broadly	similar	patterns	for	acute	andchronic	inflammation		relative	to	europe		prevalence	of	acute	inflammation	washigher	in	north	america	[odds	ratio	(or)		1	77		95%	confidence	interval	(ci)	1	51-2	08]	and	australia/new	zealand	(or		2	07		95%	ci		1	40-3	06)		men	fromthese	regions	had	lower	prostate	cancer	risk	than	europeans	at	biopsy		amongnorth	americans		prevalence	of	acute	inflammation	was	higher	in	canada	versus	theunited	states	(or		1	40		95%	ci		1	07-1	83)		but	prostate	cancer	risk	did	notdiffer	between	these	regions		among	europeans		prevalence	of	acute	inflammationwas	lower	in	northern	and	eastern	(or		0	79		95%	ci		0	65-0	97	and	or	0	62		95%ci		0	45-0	87		respectively)		relative	to	western	europe		and	these	men	hadhigher	prostate	cancer	risk	at	biopsy	conclusions		prevalence	of	histologicprostate	inflammation	varied	by	region		geographic	differences	in	prostateinflammation	tracked	inversely	with	geographic	differences	in	prostate	cancerrisk	impact		characterization	of	premalignant	prostate	biology	and	therelationship	with	subsequent	prostate	cancer	risk	could	inform	prostate	cancerprevention	efforts		cancer	epidemiol	biomarkers	prev		27(7)		783-9		Â©2018	aacr	
